Stock Analysis on Net
Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Analysis of Profitability Ratios
Quarterly Data

Beginner level

Profitability Ratios (Summary)

Abbott Laboratories, profitability ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Return on Sales
Gross profit margin 50.49% 50.18% 50.97% 52.13% 52.46% 52.39% 52.17% 51.57% 51.32% 50.57% 50.38% 49.39% 47.75% 48.59% 49.21% 51.32% 54.09%
Operating profit margin 15.48% 13.39% 12.78% 14.18% 14.21% 13.74% 13.27% 12.31% 11.94% 10.45% 10.11% 8.92% 6.30% 7.89% 8.77% 11.03% 15.27%
Net profit margin 12.99% 10.50% 9.89% 11.15% 11.56% 10.50% 9.36% 8.53% 7.74% 2.91% 3.13% 1.67% 1.74% 8.37% 4.96% 6.74% 6.71%
Return on Investment
Return on equity (ROE) 13.71% 10.78% 10.17% 11.84% 11.86% 10.35% 9.14% 8.48% 7.76% 2.89% 3.03% 1.52% 1.54% 6.57% 3.71% 4.79% 6.82%
Return on assets (ROA) 6.20% 4.90% 4.52% 5.36% 5.43% 4.80% 4.23% 3.88% 3.53% 1.24% 1.35% 0.67% 0.63% 2.91% 1.65% 2.12% 2.66%

Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-07-29), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-22), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Abbott Laboratories’s gross profit margin ratio deteriorated from Q2 2020 to Q3 2020 but then slightly improved from Q3 2020 to Q4 2020.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Abbott Laboratories’s operating profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Abbott Laboratories’s net profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Abbott Laboratories’s ROE improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.
ROA A profitability ratio calculated as net income divided by total assets. Abbott Laboratories’s ROA improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.

Gross Profit Margin

Abbott Laboratories, gross profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in millions)
Gross profit 5,700  4,377  3,512  3,884  4,397  4,234  4,217  3,889  4,086  3,946  3,923  3,739  3,766  3,471  3,072  2,769  2,900  2,877  2,901  2,601 
Net sales 10,701  8,853  7,328  7,726  8,314  8,076  7,979  7,535  7,765  7,656  7,767  7,390  7,589  6,829  6,637  6,335  5,333  5,302  5,333  4,885 
Profitability Ratio
Gross profit margin1 50.49% 50.18% 50.97% 52.13% 52.46% 52.39% 52.17% 51.57% 51.32% 50.57% 50.38% 49.39% 47.75% 48.59% 49.21% 51.32% 54.09%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc. 66.41% 68.74% 73.56% 77.43% 77.64% 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05% 76.85% 76.78% 76.81% 77.25%
Amgen Inc. 74.59% 75.55% 77.15% 78.90% 80.38% 81.19% 81.23% 81.26% 81.80% 81.61% 81.78% 81.69% 81.33% 81.37% 81.26% 81.05% 80.99%
Bristol-Myers Squibb Co. 72.31% 71.18% 69.47% 68.02% 69.10% 69.90% 70.10% 70.86% 70.98% 70.37% 70.12% 69.62% 70.80% 71.92% 72.78% 74.19% 74.54%
Eli Lilly & Co. 77.66% 78.26% 78.67% 79.22% 78.85% 77.78% 76.67% 74.96% 73.81% 73.39% 72.92% 72.95% 73.46% 73.69% 73.89% 73.78% 73.35%
Gilead Sciences Inc. 81.23% 78.72% 78.25% 79.06% 78.86% 79.27% 78.98% 78.02% 77.61% 79.21% 80.31% 81.82% 82.97% 84.51% 84.71% 85.95% 85.77%
Illumina Inc. 68.01% 69.02% 70.34% 70.36% 69.63% 69.24% 68.84% 69.06% 69.01% 69.44% 68.85% 67.98% 66.35% 65.68% 66.26% 67.53% 69.48%
Johnson & Johnson 65.58% 65.68% 65.66% 66.15% 66.42% 66.49% 66.67% 66.80% 66.79% 66.36% 65.69% 66.22% 66.84% 68.20% 69.35% 69.88% 69.84%
Merck & Co. Inc. 67.74% 71.23% 70.06% 70.11% 69.87% 70.13% 69.89% 68.94% 68.06% 67.35% 67.81% 68.22% 68.16% 68.09% 67.92% 66.61% 65.10%
Pfizer Inc. 79.26% 79.86% 79.94% 79.94% 80.25% 79.85% 79.91% 79.36% 79.03% 78.58% 78.24% 78.48% 78.61% 78.66% 78.15% 77.28% 76.66%
Regeneron Pharmaceuticals Inc. 86.82% 87.98% 88.21% 89.72% 90.05% 91.14% 92.27% 92.79% 93.53% 93.36% 93.28% 92.95% 93.24% 93.37% 94.16% 94.53% 93.83%
Vertex Pharmaceuticals Inc. 88.14% 88.01% 87.71% 87.24% 86.84% 86.60% 86.56% 86.74% 86.56% 86.88% 87.31% 87.59% 88.95% 89.04% 89.08% 89.76% 87.64%
Zoetis Inc. 69.18% 69.64% 69.73% 69.51% 68.18% 67.38% 66.92% 66.49% 67.19% 68.12% 68.04% 67.31% 66.55% 65.14% 64.91% 65.30% 65.92%

Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-07-29), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-22), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04).

1 Q4 2020 Calculation
Gross profit margin = 100 × (Gross profitQ4 2020 + Gross profitQ3 2020 + Gross profitQ2 2020 + Gross profitQ1 2020) ÷ (Net salesQ4 2020 + Net salesQ3 2020 + Net salesQ2 2020 + Net salesQ1 2020)
= 100 × (5,700 + 4,377 + 3,512 + 3,884) ÷ (10,701 + 8,853 + 7,328 + 7,726) = 50.49%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Abbott Laboratories’s gross profit margin ratio deteriorated from Q2 2020 to Q3 2020 but then slightly improved from Q3 2020 to Q4 2020.

Operating Profit Margin

Abbott Laboratories, operating profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in millions)
Operating earnings (loss) 2,432  1,495  672  758  1,389  1,198  1,206  739  1,165  995  882  608  691  810  427  (202) 948  897  816  524 
Net sales 10,701  8,853  7,328  7,726  8,314  8,076  7,979  7,535  7,765  7,656  7,767  7,390  7,589  6,829  6,637  6,335  5,333  5,302  5,333  4,885 
Profitability Ratio
Operating profit margin1 15.48% 13.39% 12.78% 14.18% 14.21% 13.74% 13.27% 12.31% 11.94% 10.45% 10.11% 8.92% 6.30% 7.89% 8.77% 11.03% 15.27%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 24.81% 28.45% 30.17% 39.86% 39.03% 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99% 37.24% 36.74% 36.33% 36.60%
Amgen Inc. 37.70% 38.59% 39.76% 41.89% 43.57% 44.83% 44.05% 44.53% 45.55% 45.82% 46.46% 46.07% 45.76% 46.66% 46.93% 45.68% 44.74%
Bristol-Myers Squibb Co. -21.60% 9.27% 11.67% 16.30% 22.62% 28.63% 28.59% 23.43% 22.69% 18.64% 15.93% 17.50% 17.39% 19.71% 21.73% 24.06% 23.83%
Eli Lilly & Co. 24.69% 23.55% 24.48% 25.64% 22.29% 20.00% 19.48% 12.50% 15.15% 12.34% 9.11% 14.88% 9.38% 12.43% 14.23% 12.92% 16.30%
Gilead Sciences Inc. 16.72% 11.01% -4.40% 19.89% 19.38% 19.71% 38.44% 37.87% 37.83% 42.81% 46.25% 51.51% 55.04% 58.72% 58.71% 58.46% 58.87%
Illumina Inc. 17.91% 22.08% 25.69% 27.28% 27.80% 26.42% 24.88% 25.58% 26.49% 28.25% 27.58% 26.29% 22.02% 20.01% 20.06% 21.35% 24.48%
Johnson & Johnson 23.60% 24.30% 24.64% 25.62% 24.15% 24.15% 22.63% 22.69% 24.27% 22.59% 23.05% 23.63% 24.07% 27.02% 28.55% 28.83% 28.72%
Merck & Co. Inc. 16.47% 26.87% 25.40% 25.49% 24.77% 25.56% 26.73% 24.38% 19.62% 17.84% 12.28% 13.57% 16.28% 9.92% 16.85% 14.45% 13.51%
Pfizer Inc. 19.47% 24.77% 23.75% 25.38% 25.46% 26.30% 27.50% 26.86% 26.10% 26.18% 26.00% 25.86% 25.92% 24.69% 23.57% 22.94% 22.73%
Regeneron Pharmaceuticals Inc. 42.09% 37.43% 34.64% 30.45% 28.10% 29.55% 29.58% 35.41% 37.77% 37.00% 36.89% 36.54% 35.41% 34.22% 32.29% 28.76% 27.38%
Vertex Pharmaceuticals Inc. 46.03% 44.43% 38.67% 34.05% 28.77% 21.38% 25.48% 23.98% 20.84% 22.38% 3.87% -0.77% 4.95% 1.62% 16.16% 14.62% 0.58%
Zoetis Inc. 33.62% 33.87% 33.36% 32.72% 31.42% 31.01% 29.80% 30.05% 31.12% 33.00% 33.86% 33.02% 32.15% 29.43% 28.34% 28.55% 28.48%

Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-07-29), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-22), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04).

1 Q4 2020 Calculation
Operating profit margin = 100 × (Operating earnings (loss)Q4 2020 + Operating earnings (loss)Q3 2020 + Operating earnings (loss)Q2 2020 + Operating earnings (loss)Q1 2020) ÷ (Net salesQ4 2020 + Net salesQ3 2020 + Net salesQ2 2020 + Net salesQ1 2020)
= 100 × (2,432 + 1,495 + 672 + 758) ÷ (10,701 + 8,853 + 7,328 + 7,726) = 15.48%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Abbott Laboratories’s operating profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.

Net Profit Margin

Abbott Laboratories, net profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in millions)
Net earnings (loss) 2,162  1,232  537  564  1,049  960  1,006  672  654  563  733  418  (828) 603  283  419  798  (329) 615  316 
Net sales 10,701  8,853  7,328  7,726  8,314  8,076  7,979  7,535  7,765  7,656  7,767  7,390  7,589  6,829  6,637  6,335  5,333  5,302  5,333  4,885 
Profitability Ratio
Net profit margin1 12.99% 10.50% 9.89% 11.15% 11.56% 10.50% 9.36% 8.53% 7.74% 2.91% 3.13% 1.67% 1.74% 8.37% 4.96% 6.74% 6.71%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 10.08% 18.16% 19.20% 24.77% 23.69% 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82% 24.38% 24.77% 24.07% 23.22%
Amgen Inc. 29.97% 30.91% 31.53% 33.64% 35.32% 36.14% 35.57% 35.93% 37.25% 9.96% 10.72% 10.11% 9.08% 37.36% 37.24% 36.12% 35.27%
Bristol-Myers Squibb Co. -21.20% -0.11% -1.61% 3.08% 13.15% 23.39% 26.00% 22.09% 21.81% 6.50% 1.74% 4.37% 4.85% 20.56% 22.66% 24.22% 22.94%
Eli Lilly & Co. 25.24% 24.01% 24.48% 23.97% 37.27% 35.10% 33.76% 26.12% 13.16% 1.85% -0.60% 4.82% -0.89% 9.90% 11.12% 10.13% 12.90%
Gilead Sciences Inc. 0.51% 5.56% -1.18% 22.17% 24.35% 12.24% 27.14% 26.93% 25.16% 7.27% 9.69% 14.26% 18.03% 42.90% 43.55% 44.11% 45.07%
Illumina Inc. 20.25% 19.70% 20.68% 26.49% 28.28% 28.13% 27.55% 25.05% 24.78% 21.09% 20.88% 19.31% 26.38% 30.14% 30.07% 30.52% 19.29%
Johnson & Johnson 17.82% 21.01% 18.86% 20.75% 18.42% 17.32% 20.08% 17.99% 18.75% 1.89% 1.70% 1.58% 1.70% 21.28% 22.52% 22.87% 23.01%
Merck & Co. Inc. 14.72% 24.33% 22.20% 21.10% 21.01% 20.26% 21.10% 19.50% 14.71% 8.02% 3.25% 3.88% 5.97% 7.15% 12.71% 10.88% 9.85%
Pfizer Inc. 22.95% 17.85% 28.80% 31.17% 31.45% 30.57% 23.58% 21.31% 20.79% 44.63% 42.35% 41.29% 40.55% 18.69% 15.90% 13.88% 13.66%
Regeneron Pharmaceuticals Inc. 41.35% 38.28% 37.30% 28.56% 26.91% 28.13% 28.59% 35.12% 36.42% 28.24% 25.65% 23.54% 20.41% 23.17% 22.05% 19.34% 18.42%
Vertex Pharmaceuticals Inc. 43.70% 44.91% 38.51% 31.35% 28.27% 59.23% 64.13% 66.01% 68.80% 22.87% 15.84% 9.36% 10.59% 8.53% 12.19% 8.78% -6.58%
Zoetis Inc. 24.54% 25.42% 25.50% 25.41% 23.96% 23.76% 22.74% 23.47% 24.52% 20.35% 19.95% 17.97% 16.28% 18.29% 17.50% 17.25% 16.80%

Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-07-29), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-22), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04).

1 Q4 2020 Calculation
Net profit margin = 100 × (Net earnings (loss)Q4 2020 + Net earnings (loss)Q3 2020 + Net earnings (loss)Q2 2020 + Net earnings (loss)Q1 2020) ÷ (Net salesQ4 2020 + Net salesQ3 2020 + Net salesQ2 2020 + Net salesQ1 2020)
= 100 × (2,162 + 1,232 + 537 + 564) ÷ (10,701 + 8,853 + 7,328 + 7,726) = 12.99%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Abbott Laboratories’s net profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.

Return on Equity (ROE)

Abbott Laboratories, ROE calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in millions)
Net earnings (loss) 2,162  1,232  537  564  1,049  960  1,006  672  654  563  733  418  (828) 603  283  419  798  (329) 615  316 
Total Abbott shareholders’ investment 32,784  31,386  30,578  30,218  31,088  31,817  31,686  30,925  30,524  30,705  30,577  31,399  30,897  32,032  31,602  31,362  20,538  20,776  20,675  20,722 
Profitability Ratio
ROE1 13.71% 10.78% 10.17% 11.84% 11.86% 10.35% 9.14% 8.48% 7.76% 2.89% 3.03% 1.52% 1.54% 6.57% 3.71% 4.79% 6.82%
Benchmarks
ROE, Competitors2
AbbVie Inc. 35.30% 48.34% 47.30% 179.59% 104.16% 99.42% 110.08% 126.25% 128.41%
Amgen Inc. 77.20% 67.09% 68.48% 80.92% 81.07% 73.83% 73.73% 74.55% 67.15% 15.35% 15.86% 14.21% 7.84% 25.37% 25.77% 25.76% 25.85%
Bristol-Myers Squibb Co. -23.84% -0.09% -1.15% 1.91% 6.66% 32.04% 38.65% 33.80% 35.07% 10.50% 3.05% 7.18% 8.58% 28.61% 31.20% 33.55% 27.55%
Eli Lilly & Co. 109.79% 115.45% 137.26% 179.72% 319.09% 234.97% 282.08% 252.24% 32.88% 3.44% -1.24% 7.74% -1.76% 14.94% 17.35% 15.58% 19.54%
Gilead Sciences Inc. 0.68% 7.27% -1.43% 22.49% 23.91% 13.07% 26.33% 26.84% 25.51% 6.94% 10.19% 16.82% 22.64% 46.69% 53.86% 61.82% 71.48%
Illumina Inc. 13.98% 13.57% 15.19% 20.32% 21.72% 21.92% 21.65% 21.36% 21.98% 19.53% 19.90% 18.85% 26.41% 27.38% 27.54% 29.01% 21.06%
Johnson & Johnson 23.25% 26.35% 24.11% 28.01% 25.42% 24.31% 26.87% 24.90% 25.60% 2.39% 2.18% 1.97% 2.16% 21.39% 22.71% 23.46% 23.49%
Merck & Co. Inc. 27.91% 39.47% 37.91% 38.72% 37.99% 34.70% 33.88% 30.50% 23.30% 10.32% 4.12% 4.69% 6.97% 7.44% 12.89% 10.91% 9.78%
Pfizer Inc. 15.21% 13.31% 22.02% 24.28% 25.77% 24.91% 21.24% 19.52% 17.59% 33.40% 32.31% 29.72% 29.88% 16.14% 14.26% 12.49% 12.12%
Regeneron Pharmaceuticals Inc. 31.86% 31.17% 32.94% 18.79% 19.08% 20.41% 21.21% 25.70% 27.91% 22.85% 22.14% 21.74% 19.51% 21.12% 20.91% 19.79% 20.13%
Vertex Pharmaceuticals Inc. 31.22% 33.08% 27.67% 23.38% 19.34% 40.81% 43.70% 45.63% 47.28% 22.27% 15.46% 9.41% 12.99% 10.93% 15.55% 11.82% -9.69%
Zoetis Inc. 43.46% 46.17% 54.23% 58.52% 55.39% 54.56% 57.03% 59.91% 65.35% 54.96% 56.60% 49.90% 48.81% 47.11% 51.20% 53.14% 55.21%

Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-07-29), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-22), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04).

1 Q4 2020 Calculation
ROE = 100 × (Net earnings (loss)Q4 2020 + Net earnings (loss)Q3 2020 + Net earnings (loss)Q2 2020 + Net earnings (loss)Q1 2020) ÷ Total Abbott shareholders’ investment
= 100 × (2,162 + 1,232 + 537 + 564) ÷ 32,784 = 13.71%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Abbott Laboratories’s ROE improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.

Return on Assets (ROA)

Abbott Laboratories, ROA calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in millions)
Net earnings (loss) 2,162  1,232  537  564  1,049  960  1,006  672  654  563  733  418  (828) 603  283  419  798  (329) 615  316 
Total assets 72,548  69,043  68,776  66,777  67,887  68,539  68,427  67,610  67,173  71,637  68,415  70,908  76,250  72,248  71,151  70,887  52,666  39,497  39,831  39,637 
Profitability Ratio
ROA1 6.20% 4.90% 4.52% 5.36% 5.43% 4.80% 4.23% 3.88% 3.53% 1.24% 1.35% 0.67% 0.63% 2.91% 1.65% 2.12% 2.66%
Benchmarks
ROA, Competitors2
AbbVie Inc. 3.07% 4.93% 4.65% 9.25% 8.84% 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50% 9.66% 9.87% 9.61% 9.01%
Amgen Inc. 11.54% 11.37% 11.23% 12.45% 13.13% 13.55% 13.40% 12.62% 12.64% 3.27% 3.49% 3.12% 2.48% 10.18% 10.27% 10.14% 9.95%
Bristol-Myers Squibb Co. -7.61% -0.04% -0.44% 0.74% 2.65% 9.85% 11.24% 14.77% 14.06% 4.24% 1.15% 2.78% 3.00% 12.45% 13.73% 14.68% 13.22%
Eli Lilly & Co. 13.28% 12.68% 13.39% 13.46% 21.17% 20.97% 20.28% 16.46% 7.36% 1.01% -0.34% 2.53% -0.45% 5.17% 5.98% 5.81% 7.05%
Gilead Sciences Inc. 0.18% 2.08% -0.46% 8.31% 8.74% 4.55% 9.42% 9.38% 8.57% 2.47% 3.38% 5.30% 6.58% 17.94% 20.27% 21.90% 23.70%
Illumina Inc. 8.65% 8.62% 9.56% 12.97% 13.70% 13.73% 13.45% 11.52% 11.87% 10.12% 11.08% 10.23% 13.81% 15.49% 15.39% 16.10% 10.81%
Johnson & Johnson 8.41% 9.95% 9.59% 11.07% 9.59% 9.10% 10.53% 9.78% 10.00% 0.99% 0.88% 0.79% 0.83% 10.17% 10.69% 11.39% 11.71%
Merck & Co. Inc. 7.72% 12.83% 11.56% 11.95% 11.66% 11.18% 11.15% 10.20% 7.53% 3.93% 1.58% 1.84% 2.72% 3.11% 5.48% 4.50% 4.11%
Pfizer Inc. 6.23% 4.85% 7.96% 9.49% 9.72% 9.51% 8.10% 7.38% 7.00% 14.19% 13.67% 13.21% 12.40% 5.70% 4.94% 4.32% 4.20%
Regeneron Pharmaceuticals Inc. 20.47% 19.62% 20.68% 14.46% 14.29% 15.38% 15.71% 18.88% 20.83% 16.64% 15.99% 15.23% 13.67% 14.69% 14.24% 12.32% 12.84%
Vertex Pharmaceuticals Inc. 23.07% 23.81% 20.37% 16.99% 14.15% 28.53% 31.50% 32.94% 33.57% 14.00% 9.58% 5.72% 7.43% 6.12% 7.91% 6.02% -3.87%
Zoetis Inc. 12.04% 12.12% 12.37% 13.97% 12.99% 12.96% 12.52% 12.75% 13.25% 11.13% 12.96% 11.25% 10.06% 10.09% 11.25% 11.18% 10.73%

Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-07-29), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-22), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04).

1 Q4 2020 Calculation
ROA = 100 × (Net earnings (loss)Q4 2020 + Net earnings (loss)Q3 2020 + Net earnings (loss)Q2 2020 + Net earnings (loss)Q1 2020) ÷ Total assets
= 100 × (2,162 + 1,232 + 537 + 564) ÷ 72,548 = 6.20%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Abbott Laboratories’s ROA improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.